U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H19NO
Molecular Weight 205.2961
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Diethylpropion

SMILES

CCN(CC)C(C)C(=O)C1=CC=CC=C1

InChI

InChIKey=XXEPPPIWZFICOJ-UHFFFAOYSA-N
InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C13H19NO
Molecular Weight 205.2961
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine. Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. It is used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.

CNS Activity

Curator's Comment: exerts its effects in the brain in a similar manner to amphetamine, stimulating the release as well as inhibiting the reuptake of neurotransmitters such as DA, NE, and 5-HT

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.014 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TENUATE

Approved Use

TENUATE and TENUATE DOSPAN are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.

Launch Date

1959
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.04 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLPROPION plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.59 ng × h/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLPROPION plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.95 h
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLPROPION plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
120 mg 1 times / day multiple, oral
Studied dose
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Long-term use of diethylpropion in obesity.
1973
Some chemical and stereochemical aspects of diethylpropion metabolism in man.
1973 Dec
Proceedings: Pharmacokinetic and stereo-chemical studies on diethylpropion and related compounds in man.
1974 Dec
The stereochemistry of carbonyl reduction of diethylpropion and related amino-ketones in man.
1974 Dec 1
Schizophrenia-like reaction to diethylpropion.
1976 Nov 27
Diethylpropion and paranoid psychosis.
1979 Mar
Diethylpropion and psychosis.
1988 Apr
Enantioseparation of amfepramone (rac-diethylpropion): preparative separation of the enantiomers and enantioselective analysis.
1999
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety.
2001 Aug 13-27
[Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified].
2001 Oct 20
WHO Expert Committee on Drug Dependence.
2003
Obesity.
2003 Dec
Effects of diethylpropion treatment and withdrawal on aorta reactivity, endothelial factors and rat behavior.
2003 Jul 15
High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy.
2003 May
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
2003 Sep
Obesity: an overview on its current perspectives and treatment options.
2004 Apr 14
Homeopathic products, not as innocent and safe as they seem? A case report.
2004 Aug
Pharmacological and surgical treatment of obesity.
2004 Jul
Obesity.
2004 Jun
[Determination of fenfluramine, diethylpropion and mazindol in slimming foods by gas chromatography-mass spectrometry].
2004 May
Amfepramone does not cause primary pulmonary hypertension.
2004 May
[Pharmacotherapy of obesity].
2004 Oct 7
Pharmacotherapy for obesity.
2005
Diabesity: are weight loss medications effective?
2005
Meta-analysis: pharmacologic treatment of obesity.
2005 Apr 5
Phentermine and anaesthesia.
2005 Aug
Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland.
2005 Feb
Obesity.
2005 Jun
Serotonin1A-receptor antagonism blocks psychostimulant properties of diethylpropion in marmosets (Callithrix penicillata).
2005 Mar 21
Safety of obesity drugs.
2005 Nov
Safety of drug therapies used for weight loss and treatment of obesity.
2006
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine.
2009
Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion.
2009
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
2009 Aug
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
2009 Jun
The sirenomelia sequence: a case history.
2010
A new method for the simultaneous determination of 1,4-benzodiazepines and amfepramone as adulterants in phytotherapeutic formulations by voltammetry.
2010 Oct 10
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:09:17 GMT 2023
Edited
by admin
on Fri Dec 15 17:09:17 GMT 2023
Record UNII
Q94YYU22B8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Diethylpropion
MI   VANDF  
Common Name English
DIETHYLPROPION [MI]
Common Name English
DIETHYLCATHINONE
Common Name English
D07444
Code English
AMFEPRAMONE [HSDB]
Common Name English
Amfepramone
HSDB   INN   WHO-DD  
INN  
Official Name English
DIETHYLPROPION [VANDF]
Common Name English
Amfepramone [WHO-DD]
Common Name English
1-PROPANONE, 2-(DIETHYLAMINO)-1-PHENYL-
Systematic Name English
2-(DIETHYLAMINO)-1-PHENYL-1-PROPANONE
Systematic Name English
.ALPHA.-BENZOYLTRIETHYLAMINE
Common Name English
2-(DIETHYLAMINO)PROPIOPHENONE
Systematic Name English
ANFERPRAMON
Common Name English
J4.327C
Code English
2-DIETHYLAMINOPROPIOPHENONE
Systematic Name English
amfepramone [INN]
Common Name English
C06954
Code English
ANFEPRAMONE
Common Name English
Classification Tree Code System Code
DEA NO. 1610
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
NDF-RT N0000175423
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
NDF-RT N0000175651
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
WHO-ATC A08AA03
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
NDF-RT N0000175372
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
WHO-VATC QA08AA03
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
NCI_THESAURUS C29728
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
NDF-RT N0000175372
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
NCI_THESAURUS C47795
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
LIVERTOX NBK548787
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL1194666
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
ECHA (EC/EINECS)
202-019-1
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
CHEBI
4530
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
FDA UNII
Q94YYU22B8
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
IUPHAR
7161
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
SMS_ID
100000087197
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
MESH
D004053
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
DRUG CENTRAL
874
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
DRUG BANK
DB00937
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
INN
974
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
EVMPD
SUB05417MIG
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
WIKIPEDIA
AMFEPRAMONE
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
DAILYMED
Q94YYU22B8
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
PUBCHEM
7029
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID6022929
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
NCI_THESAURUS
C61721
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
RXCUI
3389
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY RxNorm
CAS
90-84-6
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
MERCK INDEX
m4415
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY Merck Index
HSDB
3059
Created by admin on Fri Dec 15 17:09:17 GMT 2023 , Edited by admin on Fri Dec 15 17:09:17 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
METABOLITE -> PARENT
Norpseudoephedrine is a major metabolite of diethylpropion in man under acidic urine conditions.
METABOLITE ACTIVE -> PRODRUG
Dopamine: uptake IC50= 1014 +/- 80 nM, release IC50= >1000 nM; Norepinephrine: uptake IC50= 360 +/- 29 nM, release IC50= 99.3 +/- 6.6 nM; Serotonin: uptake IC50= 3840 +/- 240 nM, release IC50= 2118 +/- 98 nM
IN-VITRO
IC50